Keratinocyte Growth Factor to Prevent Acute GVHD
NCT00031148 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 72
Last updated 2015-03-25
Summary
This is a study to determine the safety and efficacy of keratinocyte growth factor (KGF) to prevent acute graft-versus-host disease (GVHD) in patients undergoing allogeneic bone marrow (BM) or peripheral blood progenitor cell (PBPC) transplantation.
Conditions
- Graft-vs-Host Disease
Interventions
- DRUG
-
Recombinant Human Keratinocyte Growth Factor (rHuKGF)
Sponsors & Collaborators
-
FDA Office of Orphan Products Development
lead FED
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- DOUBLE
Eligibility
- Min Age
- 3 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2001-09-30
- Completion
- 2003-08-31
Countries
- United States
Study Locations
More Related Trials
-
Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis
NCT02065154 ·Status: COMPLETED ·Phase: PHASE2
-
GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant
NCT02360111 ·Status: TERMINATED ·Phase: NA
-
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
NCT02145403 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
NCT06859424 ·Status: RECRUITING ·Phase: PHASE2
-
Recombinant Human Growth Hormone (RH-GH) For Accelerating Immune Reconstitution Post Unrelated Cord Blood Transplant
NCT00737113 ·Status: TERMINATED ·Phase: PHASE1
-
Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation
NCT03602898 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study of Etanercept for the Prevention of Complications Resulting From Hematopoietic Stem Cell Transplantation (HSCT)
NCT00141739 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
NCT00224874 ·Status: COMPLETED ·Phase: PHASE2
-
Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
NCT00005641 ·Status: TERMINATED ·Phase: PHASE2
-
Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
NCT00186628 ·Status: COMPLETED ·Phase: PHASE2
-
Study of MEDI 507 in the Treatment of Pediatric Patients
NCT00813618 ·Status: COMPLETED ·Phase: PHASE1
-
Haplo Peripheral Blood Sct In GVHD Prevention
NCT04473911 ·Status: COMPLETED ·Phase: PHASE1
-
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
NCT02208037 ·Status: COMPLETED ·Phase: PHASE2
-
Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation
NCT07025538 ·Status: RECRUITING ·Phase: PHASE1
-
Pharmacokinetics-based Mycophenolate Mofetil Dosing for GVHD Prevention
NCT01487577 ·Status: COMPLETED ·Phase: PHASE2
-
Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)
NCT04095858 ·Status: TERMINATED ·Phase: PHASE3
-
Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia
NCT06752694 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease
NCT05121142 ·Status: COMPLETED ·Phase: PHASE1
-
Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)
NCT01295710 ·Status: COMPLETED ·Phase: PHASE3
-
Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
NCT06128070 ·Status: RECRUITING ·Phase: PHASE2
-
Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant
NCT06315309 ·Status: RECRUITING ·Phase: PHASE2
-
Tissue Repair in Stem Cell Transplant Recipients
NCT00501228 ·Status: TERMINATED ·Phase: NA
-
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
NCT06839456 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
NCT06001385 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
NCT03986086 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2